IMMUNEONCO-B (01541) released its interim performance, with revenue of 38.027 million yuan, a year-on-year increase of 49285.71%.

IMMUNEONCO-B (01541) released its interim performance for the six months ending June 30, 2025, with revenue of 38.027 million yuan (RMB, the same below), a year-on-year increase of 49285.71%; research and development expenditure was 168 million yuan, a year-on-year increase of 41.05%. The announcement stated that the increase in revenue was mainly attributable to recent payments received by the group under the authorization and cooperation agreement with Axion Bio, Inc. The increase in research and development expenses was mainly attributed to: (i) an increase of 43.4 million yuan in preclinical and CMC expenses (mainly due to production and CDMO expenses for IMM01, IMM2510, and IMM0306 used in clinical trials); (ii) an increase of 8.3 million yuan in clinical trial expenses (mainly due to continued clinical development of IMM01 and IMM2510); and (iii) an increase of 4.9 million yuan in salaries and related benefits due to the expansion of the group's clinical team, in line with the group's continued advancement and expansion of its drug pipeline; partially offset by a decrease of 6.7 million yuan in equity-based payments (due to a decrease in the number of restricted shares attributed as of the six months ending on June 30, 2025).